Immucell Corp /De/ (ICCC) Stock Price & Analysis
Immucell Corp /De/ (ICCC) rose 0.91% to USD 11.03 as of July 25, 2026 at 04:51 UTC, according to Nexqual real-time market data.
ICCC last closed at USD 10.93; the session ranged USD 10.91–11.17 on volume of 8,583 shares. Market capitalization is $99.79M, with a 52-week range of USD 4.52–12.1 (NCM). Source: Nexqual, July 25, 2026 at 04:51 UTC.
Key Statistics (as of July 25, 2026 at 04:51 UTC)
| Price | USD 11.03 |
|---|---|
| Change | ▲ 0.91% (up) |
| Previous Close | USD 10.93 |
| Open | USD 10.91 |
| Day Range | USD 10.91 – 11.17 |
| 52-Week Range | USD 4.52 – 12.1 |
| Volume | 8,583 shares |
| Market Cap | $99.79M |
| Exchange | NCM |
Technical Analysis (ICCC)
Nexqual's technical model rates ICCC "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 04:51 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.11 (neutral) |
| vs SMA50 | Above (USD 10.14) |
| MACD | 0.34 (positive) |
Analyst Ratings (ICCC)
Wall Street analysts rate ICCC "None", per Nexqual as of July 25, 2026 at 04:51 UTC.
| Consensus Rating | None |
|---|
Earnings (ICCC)
| Next Earnings Date | 2026-08-13 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2020-12-31 | USD 0.03 vs est -0.04 ▲ beat |
| 2020-09-30 | USD -0.04 vs est -0.08 ▲ beat |
| 2020-06-30 | USD -0.11 vs est -0.1 ▼ miss |
Source: Nexqual, July 25, 2026 at 04:51 UTC.
Financials & Fundamentals (ICCC)
| Total Revenue | $29.93M |
|---|---|
| Revenue Growth (YoY) | +28.40% |
| Gross Margin | +42.59% |
| Operating Margin | +19.01% |
| Profit Margin | -1.82% |
| ROE | -1.88% |
| Debt / Equity | 43.86 |
| Current Ratio | 4.82 |
| Total Cash | $6.81M |
| Total Debt | $12.78M |
| Free Cash Flow | $3.18M |
Source: Nexqual, July 25, 2026 at 04:51 UTC.
Financial Health Score (ICCC)
Nexqual rates Immucell Corp /De/'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:51 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $7M cash vs $13M debt |
| Cash Flow | Strong — FCF $3M, 21% margin |
| Efficiency | Critical — ROE -2%, ROA 4.6% |
Ownership (ICCC)
| Insider Ownership | +32.13% |
|---|---|
| Institutional Ownership | +21.62% |
| Shares Outstanding | 9.05M |
| Float | 6.00M |
| Short % of Float | +0.19% |
Source: Nexqual, July 25, 2026 at 04:51 UTC.
Leadership (ICCC)
Immucell Corp /De/ is led by Paul F. Olivier Te Boekhorst (age 53), President, CEO & Director, per Nexqual as of July 25, 2026 at 04:51 UTC.
| President, CEO & Director | Paul F. Olivier Te Boekhorst (age 53) |
|---|---|
| CFO, Secretary & Treasurer | Timothy C. Fiori (age 46) |
| Senior Vice President of Sales & Marketing | Bobbi Jo Brockmann (age 48) |
| Director of Finance & Administration and Controller | Elizabeth S. Toothaker |
| Senior Director of Quality | A. Gustavo Scaffa |
Major Backers & Investors (ICCC)
Notable institutional backers of Immucell Corp /De/ include Morgan Stanley, Renaissance Technologies, Cresset Asset Management, LLC, according to Nexqual as of July 25, 2026 at 04:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 2.45% |
| Renaissance Technologies | 1.68% |
| Cresset Asset Management, LLC | 1.5% |
| Bleichroeder LP | 1.12% |
| Fidelity | 0.55% |
| Steadtrust LLC | 0.5% |
| Mesirow Financial Investment Management, Inc. | 0.47% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.23% |
| Geode Capital | 0.73% |
| Dimensional Fund Advisors | 0.62% |
Source: Nexqual, July 25, 2026 at 04:51 UTC.
From Immucell Corp /De/'s Latest SEC 10-K Filing (filed 2026-03-30)
Partnerships
- The Company markets its products through its commercial sales team, in partnership with national and regional animal‑health distributors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IRIX | IRIDEX Corporation | USD 0.89 | ▼ 3.15% |
| CSBR | Champions Oncology, Inc. | USD 6.13 | ▲ 0% |
| NAII | Natural Alternatives Internatio | USD 2.4 | ▲ 0.84% |
| CYAN | Cyanotech Corp. | USD 0.53 | ▲ 0% |
| NOTVQ | Inotiv, Inc. | USD 0.01 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:51 UTC. This page is informational and not investment advice.